Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor

Trial Profile

A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capivasertib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FAKTION
  • Most Recent Events

    • 04 Jun 2019 Primary endpoint (Phase 2 primary outcome: Progression free survival (PFS)) has been met, according to results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2019 Results of phase II part of this trial assessing the effect of addition of capivasertib to fulvestrant in postmenopausal women with ER+ and HER2 negative breast cancer after relapse or disease progression on an aromatase inhibitor, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2019 According to an AstraZeneca Media Release, data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top